WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 525774

CAS#: 137215-12-4

Description: Odiparcil is a novel, orally active beta-d-thioxyloside analog with antithrombotic activity associated with a reduced risk of adverse bleeding events. Its unique mechanism of action is postulated by means of an elevation in circulating endogenous chondroitin sulfate-related glycosaminoglycans (GAGs) levels.

Price and Availability




Odiparcil is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 525774
Name: Odiparcil
CAS#: 137215-12-4
Chemical Formula: C15H16O6S
Exact Mass: 324.0668
Molecular Weight: 324.3489
Elemental Analysis: C, 55.55; H, 4.97; O, 29.60; S, 9.89

Synonym: GSK-424323; GSK424323 GSK 424323; Odiparcil

IUPAC/Chemical Name: 4-methyl-7-(((2R,3R,4S,5S)-3,4,5-trihydroxytetrahydro-2H-thiopyran-2-yl)oxy)-2H-chromen-2-one


InChi Code: InChI=1S/C15H16O6S/c1-7-4-12(17)21-11-5-8(2-3-9(7)11)20-15-14(19)13(18)10(16)6-22-15/h2-5,10,13-16,18-19H,6H2,1H3/t10-,13+,14-,15-/m1/s1

SMILES Code: O=C1C=C(C)C2=C(O1)C=C(O[C@H]3[C@@H]([C@H]([C@@H](CS3)O)O)O)C=C2

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Myers AL, Upreti VV, Khurana M, Eddington ND. Characterization of total plasma glycosaminoglycan levels in healthy volunteers following oral administration of a novel antithrombotic odiparcil with aspirin or enoxaparin. J Clin Pharmacol. 2008 Oct;48(10):1158-70. doi: 10.1177/0091270008323751. Epub 2008 Aug 29. PubMed PMID: 18757783.
2: Toomey JR, Abboud MA, Valocik RE, Koster PF, Burns-Kurtis CL, Pillarisetti K, Danoff TM, Erhardt JA. A comparison of the beta-D-xyloside, odiparcil, to warfarin in a rat model of venous thrombosis. J Thromb Haemost. 2006 Sep;4(9):1989-96. PubMed PMID: 16961606.